stockrow
Friday 6 November 2026
Export ATRC’s income statement to Excel — free account
AtriCure, Inc.
ATRC Healthcare Medical Instruments & Supplies
AtriCure, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $534.5 million, up 14.9% from fiscal 2024.
- Revenue
- +15.0%
- EPS
- +1,583.9%
- Free cash flow
- −0.73%
- Total debt
- −17.3%
Quarter to September 2026, against a year earlier
60.70
4.83
−7.37%
Follow ATRC
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
184.08 | 129.18 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.66 | 2.39 | 2.50 | 3.53 | |
P/FCF ratio |
119.80 | 58.91 | 58.32 | 103.31 | |
P/Operating CF |
123.82 | 61.36 | (345.09) | 94.32 | |
P/B ratio |
5.15 | 2.64 | 2.80 | 3.84 | |
Price to Tangible BV |
10.67 | 5.71 | 6.53 | 9.03 | |
EV/Sales |
4.48 | 2.26 | 2.40 | 3.40 | |
EV/EBITDA |
77.28 | 37.60 | 72.75 | 157.03 | |
EV/Operating CF |
38.55 | 19.80 | 20.59 | 31.67 | |
EV/FCF |
115.21 | 55.62 | 56.05 | 99.30 | |
Quick Ratio |
3.13 | 3.02 | 2.97 | 2.87 | |
Current Ratio |
4.33 | 4.22 | 4.29 | 3.96 | |
Net Debt/EBITDA |
0.00 | (6.42) | (12.60) | (12.19) | |
Debt/Assets |
8.50% | 10.50% | 11.15% | 11.22% | |
Debt/Equity |
0.11 | 0.14 | 0.15 | 0.15 | |
Asset Turnover |
0.87 | 0.89 | 0.89 | 0.85 | |
Operating CF/Net income |
0.00 | 2.48 | (37.00) | 11.40 | |
Capex/Depreciation |
0.00 | (0.70) | (0.72) | (0.31) | |
Interest Coverage |
2.70 | 7.33 | 0.39 | 1.66 | |
Research and Development Expense of Revenue |
20.79% | 17.19% | 17.16% | 17.44% | |
Selling, General and Administrative Expense of Revenue |
53.66% | 53.75% | 59.86% | 55.76% | |
Intangible Assets out of Total Assets |
0.38 | 0.41 | 0.44 | 0.43 | |
Share Based Compensation of Revenue |
0.00% | 8.02% | 7.98% | 8.01% | |
Graham Net Nets |
0.07 | 0.14 | 0.12 | 0.08 | |
Graham Number |
8.66 | 7.19 | 0.00 | 0.00 | |
Earnings Yield |
0.54% | 0.77% | (0.33%) | (0.60%) | |
Free Cash Flow Yield |
0.83% | 1.70% | 1.71% | 0.97% | |
Revenue per Share |
3.16 | 3.16 | 2.92 | 2.94 | |
Operating CF per Share |
0.00 | 0.46 | (0.08) | 0.42 | |
Capex per Share |
0.00 | (0.08) | (0.08) | (0.03) | |
Free Cash Flow per Share |
0.00 | 0.38 | (0.16) | 0.39 | |
Cash per Share |
3.83 | 3.45 | 3.02 | 3.51 | |
Shareholders Equity per Share |
10.91 | 10.61 | 10.17 | 10.30 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.91 | 10.61 | 10.17 | 10.30 | |
Free Cash Flow |
23.93 | 18.43 | (7.85) | 18.43 | |
Working Capital |
279.42 | 263.62 | 240.50 | 241.00 | |
Capital Expenditures |
(6.39) | (3.77) | (3.85) | (1.60) | |
Net Current Asset Value |
179.08 | 185.32 | 161.40 | 160.27 | |
EV/EBIT |
155.12 | 99.74 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.02 | 0.03 | 0.01 | |
Price to Operating Income |
161.30 | 105.64 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
69.55 | 72.99 | 67.32 | 63.50 | |
Average Payables |
52.86 | 30.76 | 27.87 | 25.17 | |
Average Inventory |
83.13 | 80.13 | 78.03 | 76.91 | |
Average Assets |
676.49 | 642.75 | 617.81 | 631.75 | |
Average Common Equity |
504.87 | 490.46 | 473.16 | 476.45 |
Columns are period end dates · fundamentals updated 5 Nov 2026